Beam Therapeutics Inc (BEAM)
23.13
+0.41
(+1.80%)
USD |
NASDAQ |
May 03, 16:00
23.12
-0.01
(-0.04%)
After-Hours: 20:00
Beam Therapeutics Revenue (Quarterly): 316.19M for Dec. 31, 2023
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
December 31, 2023 | 316.19M |
September 30, 2023 | 17.19M |
June 30, 2023 | 20.12M |
March 31, 2023 | 24.21M |
December 31, 2022 | 20.04M |
September 30, 2022 | 15.80M |
June 30, 2022 | 16.65M |
March 31, 2022 | 8.432M |
December 31, 2021 | 51.07M |
September 30, 2021 | 0.763M |
Date | Value |
---|---|
June 30, 2021 | 0.006M |
March 31, 2021 | 0.006M |
December 31, 2020 | 0.006M |
September 30, 2020 | 0.006M |
June 30, 2020 | 0.006M |
March 31, 2020 | 0.006M |
December 31, 2019 | 0.006M |
September 30, 2019 | 0.006M |
June 30, 2019 | 0.006M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.006M
Minimum
Jun 2019
316.19M
Maximum
Dec 2023
25.82M
Average
0.763M
Median
Sep 2021
Revenue (Quarterly) Benchmarks
Eli Lilly and Co | 8.768B |
Moderna Inc | 167.00M |
Editas Medicine Inc | 60.05M |
Intellia Therapeutics Inc | -1.917M |
Perspective Therapeutics Inc | -5.239M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | 142.80M |
Total Expenses (Quarterly) | 183.33M |
EPS Diluted (Quarterly) | 1.73 |
Enterprise Value | 698.87M |
Profit Margin (Quarterly) | 45.16% |
Earnings Yield | -8.21% |
Normalized Earnings Yield | -8.118 |